41 results about "Bilirubin concentration" patented technology

Luminous fluxes from a xenon tube are introduced from one end of an optical fiber to an other end thereof and emerge therefrom. These luminous fluxes are incident of a skin of a person to be measured, and those diffused in the skin are incident on one end of an optical fiber through a first incident port and on one end of an optical fiber through a second incident port. The luminous fluxes from the one end are split by a dichroic mirror. The luminous fluxes reflected by the dichroic mirror are received by a photoelectric conversion element via a blue filter, and those having transmitted through the dichroic mirror are received by a photoelectric conversion element via a green filter. A concentration of bilirubin pigmented in fat of subcutaneous tissues can be accurately measured without being influenced by a difference in the thicknesses of epidermis and derma.

A system and method embodying the invention can be used to detect a characteristic or condition of a patient. A method embodying the invention may include the steps of illuminating a portion of a skin of the patient with light, detecting a frequency spectrum of light scattered from the skin, determining, from first and second portions of the spectrum, a first parameter indicative of a blood content of the skin and a second parameter indicative of a melanin content of the skin, determining, from a third portion of the spectrum, a third parameter indicative of an uncorrected bilirubin concentration, and calculating a corrected bilirubin concentration based on the first, second and third parameters.

Disclosed is a phototherapy device for treating icterus in new-born patients, comprising a light box with at least one light source arranged in the box for illuminating the patient and a support for the patient to be placed upon which is at least partially transparent or tinted as to allow the light from the light box to expose the patient from below with respect to its direction of gravity, making it possible to expose areas having a high bilirubin concentration which tend to follow the direction of gravity.

The related bilirubin adsorption material selects agarose gel as carrier activated by N, N'-carbonyldiimidazole, the dual-amido agent and dual-aldehydo agent as separation arm, and couples all of lycine, aethanolamina, arginine and n-butylamine on back end, wherein in 324mg / L blood, the adsorption capacity for former material with different coupled is: 0.71~1.21g / Lgel, 0.78~1.29g / Lgel, 0.91~1.44g / Lgel and 1.20~1.81g / Lgel, and the removal rate to bilirubin by material coupled n-butylamine is up to 50.0%. this invention has well adsorption rate with low cost.

The invention relates to a mesoporous / macropore hierarchical pore block bilirubin adsorbent material and a preparation method of the mesoporous / macropore hierarchical pore block bilirubin adsorbent material. The mesoporous / macropore hierarchical pore block bilirubin adsorbent material is prepared by using a hierarchical pore silicon dioxide block material as hard template negative type, wherein the adsorbent material is in a three-dimensional network structure which is formed by assembling and interconnecting micron-sized short bars with ordered mesoporous structures; a pore channel of the network is a macropore. The invention also provides a method for preparing the mesoporous / macropore hierarchical pore block bilirubin adsorbent material. The mesoporous / macropore hierarchical pore block bilirubin adsorbent material is high in specific surface area; the material is block type, the mechanical strength is high, so that the situation that the material is broken and particles fall off can be avoided, and the material is applicable to blood perfusion, high in absorption rate of bilirubin and high in absorption capacity of the bilirubin; along with the increase of the concentration of the bilirubin, equilibrium adsorption capacity for the bilirubin of the material is increased; and the mesoporous / macropore hierarchical pore block bilirubin adsorbent material is a novel bilirubin adsorbent material which is high in rate and high in adsorption capacity.

A transcutaneous non-invasive device and method for measuring bilirubin levels is provided. The device and method utilize optical, electrical, and mechanical means in communication with processing means to calculate the serum bilirubin concentration. Blanching pressure is applied to the tissue, whose thickness is measured. The level of bilirubin is calculated from the thickness of the tissue and the detected and measured values of radiation transmitted through the living tissue.

The invention provides a neonate pertacuneous jaundice tester comprising the following elements: a lighting module used for alternatively emitting a first light ray and a second light ray to a neonate according to a preset frequency under the control of a control module, wherein the first and second light rays contain the lights different from a preset wavelength and used for measuring the neonate bilirubin real concentration; a light acquisition module controlled by the control module so as to regularly collect first and second light rays emitted into and reflected from the neonate skin, and the collected light rays are converted to obtain corresponding a first signal and a second signal; a communication module used for outputting the first and second electric signals so as to allow the terminal, having the bilirubin concentration information, to real time monitor the neonate bilirubin concentration, thus making fast diagnosis reaction when the neonate bilirubin concentration is abnormal, reducing neonate sickening risks in the maximum level, and ensuring neonate health.

A method for detecting jaundice using an AC portion and a DC portion of a PPG signal, the bilirubin concentration being calculated according to the following equation: as shown in the picture. The jaundice detection method of the present invention applies an optical detection technique of photoelectric volume pulse waveography (PPG) Neonatal jaundice concentration detection, remove the melanin, hemoglobin and pulse wave on the detection of bilirubin concentration, can be newborns (especially in the phototherapy of newborns) to implement real-time, continuous monitoring.

The invention discloses an application of elaeagnus conferta roxb, namely the application of the elaeagnus conferta roxb in preparation of drugs for treating kidney stones, gall-stone and hyperuricemia. In the treatment of the kidney stones, the drug is used for reducing the rate of the kidney stones, improving kidney coefficient, reducing calcium content of the kidney, reducing serum urea nitrogen and reducing serum creatinine. In the treatment of the gall-stone, the elaeagnus conferta roxb is used for treating bile pigment gallstones and cholesterol gallstones; preferably in the treatment of bilirubin gallstones, the elaeagnus conferta roxb is used for reducing the rate of the gallbladder stones, calcium ion content in bile, total bilirubin concentration and free bilirubin concentration in the treatment of the bile pigment gallstones; in the treatment of the cholesterol gallstones, the elaeagnus conferta roxb is used for reducing the rate of the gallbladder stones and the cholesterol content in the bile; and in the treatment of hyperuricemia, the elaeagnus conferta roxb is used for reducing uric acid content in serum. The application of the elaeagnus conferta roxb can be spread to related products of the elaeagnus conferta roxb; and the related product includes a fruit aqueous extract of the elaeagnus conferta roxb, dewatered elaeagnus conferta roxb, capsules, troches, granulas, fruit vinegar, jam and fruit juice.

The invention discloses a neonatal jaundice therapeutic instrument. On the basis of real-time monitoring of the bilirubin concentration in blood of the newborn, the treatment efficiency of the neonatal jaundice can be improved substantially. The neonatal jaundice therapeutic instrument is characterized in that one end of a cable connector is connected to a photoelectric source case and the other end of the cable connector is connected with a blue-light treatment blanket by an optical fiber hose. The blue-light treatment blanket consists of a light transmitting layer, a light leakage layer, a reflective layer and a constant temperature layer; optical fibers and fabric filaments are knitted, woven, or wound to form the light leakage layer; and the constant temperature layer is made of a material with a melting point of 30 to 38 DEG C. A jaundice detection module connected with the photoelectric source case electrically is used for feeding back real-time monitoring data of bilirubin in the blood of the newborn to the photoelectric source case. The neonatal jaundice therapeutic instrument is suitable for the newborn nursing after delivery, especially for treatment of diseases like the neonatal jaundice and serves as one of necessary devices of a delivery room, a newborn room, or a newborn monitoring center.

A joint point-of-care testing (POCT) analyzer, and a system comprising an analyzer and a cartridge, for measuring one or more analyte quantities per unit volume of blood and one or more formed element quantities per unit volume of blood, is described. Examples of formed elements of blood are red blood cells and white blood cells, and cell counts are determined by imaging using a two-dimensional multi-channel detector. Examples of analytes are hemoglobin and bilirubin, and hemoglobin and bilirubin concentrations are determined by spectroscopy using a one-dimensional multi-channel detector. Other examples of analytes are electrolytes, and electrolyte concentrations may be determined using biosensors incorporated in the cartridges.

The related bilirubin adsorption material selects agarose gel as carrier activated by N, N'-carbonyldiimidazole, the dual-amido agent and dual-aldehydo agent as separation arm, and couples all of lycine, aethanolamina, arginine and n-butylamine on back end, wherein in 324mg / L blood, the adsorption capacity for former material with different coupled is: 0.71~1.21g / Lgel, 0.78~1.29g / Lgel, 0.91~1.44g / Lgel and 1.20~1.81g / Lgel, and the removal rate to bilirubin by material coupled n-butylamine is up to 50.0%. this invention has well adsorption rate with low cost.

The invention relates to a system for predicting the risk of death of a patient. The system for predicting the risk of death of a patient comprises: a data acquisition module used for obtaining the medical history of a patient, physiological parameters of the patient and laboratory parameters of the patient, wherein the physiological parameters comprise the Glasgow Coma Scale of the patient, the heart rate of the patient, the systolic pressure of the patient and the oxygen saturation of the patient, and the laboratory parameters comprise the hemoglobin level, the leukocyte count, the creatinine concentration, the blood potassium concentration, the blood sodium concentration, the urea content, the platelet count, the total bilirubin concentration, the D-dimer level and the fibrinogen content of the patient; and a module for calculating the death risk of the patient used for calculating the information acquired in the data acquisition module so as to calculate the 7-day death rate (p) ofthe patient.

The invention discloses a bilirubin encephalopathy model production method employing a jugular vein catheter. The bilirubin encephalopathy model production method includes preparing bilirubin solution and performing animal moulding; 30 minutes after the animal moudling, processing animal and collecting samples; taking brain tissue of the animal and observing morphological changes of the brain tissue; extracting the brain tissue and preparing serum samples; obtaining data of serum and bilirubin concentration of the brain tissue; applying software SPSS13.0 to do statistic analysis. By the use of the bilirubin encephalopathy model production method, moulding success rate and stability is greatly increased, and the model is wide in promotion range and supports technical guarantee for research of the bilirubin encephalopathy.

It is disclosed a method for calibrating an electronic device for measuring the concentration of a biological compound, in particular bilirubin. The method comprises the step a) of performing (10) a plurality of reflectance measurements for each reference strip of a plurality of reference strips (110-1, 110-2,... 110-8) having respective predefined concentration values of the biological compound,the step b) of calculating (20), for each reference strip, a respective value of a statistical reflectance indicator as a function of the plurality of reflectance measurements, generating a pluralityof values of the statistical reflectance indicator, the step c) of subdividing the plurality of values of the statistical reflectance indicator into at least two subsets (I, II, III), the step d) of interpolating (41 ) the values of the statistical reflectance indicator of each subset so as to generate an interpolation curve for each subset, the step e) of calculating (43), for each pair of interpolation curves relative to two adjacent subsets (I, II), a reflectance threshold value for which the difference of the reflectance values of the pair of interpolation curves is minimum, the step f) ofselecting, for each interpolation curve, a portion delimited at least in part by the respective reflectance threshold values, said portion being associated with the respective plurality of values ofthe statistical reference indicator, and the step g) of generating (50) a calibration curve of the electronic device by combining the selected portions of the interpolation curves.

The invention relates to a blood plasma replacement dosage forecasting method, for solving the problems that the existing forecast is inaccurate and the blood plasma resources are wasted. The method includes the steps of: 1) weighing a patient and detecting his initial bilirubinen concentration and Hct. of red blood cells and inputting the weighing and detection results into a computer; 2) by computer program, calculating his individual blood plasma quantity according to a formula; 3) calculating the maximum, theoretical and minimum estimated values of blood plasma dosage according to a formula based on a blood plasma replacement model.

The invention provides a jaundice diagnosis and treatment system and a computer readable storage medium, and belongs to the technical field of medical equipment. The jaundice diagnosis and treatment system comprises a control circuit, a bilirubin detection assembly, a risk assessment circuit and a display assembly, wherein the bilirubin detection assembly is in communication connection with the control circuit and is used for detecting the bilirubin concentration of a newborn and transmitting the detected bilirubin concentration to the control circuit, so that the control circuit generates detection data according to the detected bilirubin concentration; the risk assessment circuit is in communication connection with the control circuit and is used for acquiring the detection data from thecontrol circuit and assessing the pathological jaundice risk level according to the detection data; and the display assembly is connected with the control circuit and is used for displaying the detection data and / or the pathological jaundice risk level under the control of the control circuit. The jaundice diagnosis and treatment system is convenient for timely discovery and timely treatment of pathological jaundice.

The invention relates to a method for rapidly cultivating calculus bovis which is low in cost, short in preparation cycle, stable in performance and little in side effect. The method comprises the step: obtaining natural ox bile and further comprises the following steps: (1) preparing a basic stock solution containing fibrinogen and other blood coagulation factors; (2) preparing a mixture containing deoxycholic acid, cholic acid, calcium bilirubin, cholesterol, phospholipid and calcium chloride for later use; (3) preparing mixed liquor containing taurine and trace amounts of FeSO4, MgSO4 and ZnSO4 for later use; (4) taking fresh ox bile for later use; (5) preparing an ox gall-stone sediment according to a set process; (6) separating, shaping and drying to obtain ox gall-stones. The method has the advantages that 1, the production cycle is short; 2, the method is safe and little in side effect; 3, the concentration of free bilirubin is more easily controlled; 4, the generated ox gall-stones are complete, the effective ingredients and the biological activity are better. The preparation principle and the reaction condition and process belong to a new method, and the quality of the generated calculus bovis is more stable than that of the natural calculus bovis.

This is a biochemistry detection liquid of something including the two things (bilirubin and urobilinogen). The bilirubin comprises 0.89-1.2w / v percents acidic iron trichloride, 20-25.3w / v percents trichloroacetic acid, 5 percents waterless glacial acetic acid and distilled water. The urobilinogen comprises 1.8-2.2w / v percents paradimethy-laminobenzaldehyde, 20 percents dense hydrochloric acid 5 percents waterless glacial acetic acid and distilled water. This invention offers biochemistry detection liquid and self-checking method of bilirubin and urobilinogen for the mass scoutting and checking dynamically. Through the recording curve diagram in accordance with series detecting color result one can self-judge something: 1, warning signal of health and pathogenic factor; 2, forepart detectable rate of hepatopathy; 3. the synchronous tracking monitoring of curative effect during the treating course. The above liquid offer the likelihood of carrying out all this function.

The invention provides a total bilirubin test card and a manufacturing method thereof, the test card comprises an upper cover, a gauze, a blood absorbing pad, a blood filtering film, a color developing film, a PET bottom sheet and a lower cover, and the total bilirubin test card is formed by assembling the upper cover, the gauze, the blood absorbing pad, the blood filtering film, the color developing film, the PET bottom sheet and the lower cover from top to bottom in sequence. According to the invention, the total bilirubin concentration in human serum can be rapidly, conveniently and accurately measured.

It is disclosed a method for calibrating an electronic device for measuring the concentration of a biological compound, in particular bilirubin. The method comprises the step a) of performing (10) a plurality of reflectance measurements for each reference strip of a plurality of reference strips (110-1, 110-2, . . . 110-8) having respective predefined concentration values of the biological compound, the step b) of calculating (20), for each reference strip, a respective value of a statistical reflectance indicator as a function of the plurality of reflectance measurements, generating a plurality of values of the statistical reflectance indicator, the step c) of subdividing the plurality of values of the statistical reflectance indicator into at least two subsets (I, II, III), the step d) of interpolating (41) the values of the statistical reflectance indicator of each subset so as to generate an interpolation curve for each subset, the step e) of calculating (43), for each pair of interpolation curves relative to two adjacent subsets (I, II), a reflectance threshold value for which the difference of the reflectance values of the pair of interpolation curves is minimum, the step f) of selecting, for each interpolation curve, a portion delimited at least in part by the respective reflectance threshold values, said portion being associated with the respective plurality of values of the statistical reference indicator, and the step g) of generating (50) a calibration curve of the electronic device by combining the selected portions of the interpolation curves.

A method for measuring bilirubin concentration in a sample includes preparing a sensing element, where the sensing element may include a plurality of carbon dots, adding the sample to the sensing element, where the sample may include a plurality of bilirubin molecules, obtaining a first grayscale image of the sensing element under ultra-violate (UV) irradiation, irradiating visible light with a wavelength between 470 nm and 490 nm on the sensing element, obtaining a second grayscale image of the sensing element under ultra-violate (UV) irradiation, calculating a light intensity difference by calculating a difference between a first average light intensity of the first grayscale image and a second average light intensity of the second image, and determining the bilirubin concentration based on a correlation between the bilirubin concentration and the light intensity difference.

The invention relates to diagnosis in general and more specifically a system and a method for determining the presence of jaundice in newborn babies, also known as neonatal jaundice.A main objective of the present invention is to provide a simple system and method for determining the presence of jaundice. Particularly since most deaths due to jaundice occur in low-income countries, there is a large unmet need of simple, reliable and affordable technologies able to identify at-risk newborn.The objective is accomplished through receiving a depiction of skin from an RGB sensor, and then using either an optical diffusion model of the skin or Monte Carlo simulations to calculate the bilirubin concentration. A meta model of the optical diffusion model or Monte Carlo simulations can also be used. Colour calibration is also performed by e.g. thin-plate spline interpolation.

The invention relates to diagnosis in general and more specifically a system and a method for determining the presence of jaundice in newborn babies, also known as neonatal jaundice.A main objective of the present invention is to provide a simple system and method for determining the presence of jaundice. Particularly since most deaths due to jaundice occur in low-income countries, there is a large unmet need of simple, reliable and affordable technologies able to identify at-risk newborn.The objective is accomplished through receiving a depiction of skin from an RGB sensor, and then using either an optical diffusion model of the skin or Monte Carlo simulations to calculate the bilirubin concentration. A meta model of the optical diffusion model or Monte Carlo simulations can also be used. Colour calibration is also performed by e.g. thin-plate spline interpolation.

A joint point-of-care testing (POCT) analyzer, and a system comprising an analyzer and a cartridge, for measuring one or more analyte quantities per unit volume of blood and one or more formed element quantities per unit volume of blood, is described. Examples of formed elements of blood are red blood cells and white blood cells, and cell counts are determined by imaging using a two-dimensional multi-channel detector. Examples of analytes are hemoglobin and bilirubin, and hemoglobin and bilirubin concentrations are determined by spectroscopy using a one-dimensional multi-channel detector. Other examples of analytes are electrolytes, and electrolyte concentrations may be determined using biosensors incorporated in the cartridges.

A transcutaneous non-invasive device and method for measuring bilirubin levels is provided. The device and method utilize optical, electrical, and mechanical means in communication with processing means to calculate the serum bilirubin concentration. Blanching pressure is applied to the tissue, whose thickness is measured. The level of bilirubin is calculated from the thickness of the tissue and the detected and measured values of radiation transmitted through the living tissue.

A joint point-of-care testing (POCT) analyzer, and a system comprising an analyzer and a cartridge, for measuring one or more analyte quantities per unit volume of blood and one or more formed element quantities per unit volume of blood, is described. Examples of formed elements of blood are red blood cells and white blood cells, and cell counts are determined by imaging using a two-dimensional multi-channel detector. Examples of analytes are hemoglobin and bilirubin, and hemoglobin and bilirubin concentrations are determined by spectroscopy using a one-dimensional multi-channel detector. Other examples of analytes are electrolytes, and electrolyte concentrations may be determined using biosensors incorporated in the cartridges.

The invention relates to an optical detection device and a method for concentration of components in a turbid medium based on a limited range wavelength method. The device is characterized in that a light source is connected with the turbid medium through a coupled optical fiber detecting head, the turbid medium is connected with a spectral filtering system through the coupled optical fiber detecting head, and the spectral filtering system is sequentially connected with a photoelectric detection unit, a single chip microcomputer and a display screen. The spectral filtering system is composed of a transflective prism and a light filter and is used for splitting into 2, 4, 8, ... and 2n beams of light. In the method, for the determination of limited number of wavelengths, the absorption information of bilirubin at a benchmark wavelength is adopted to remove skin background and stray light interference, and the wavelengths relevant to hemoglobin and melanin absorption with largest influence on the concentration detection of bilirubin are adopted to remove the influence of these influencing factors; and an optimal optical path length principle is adopted to calculate the optimal optical path length during the optical detection of bilirubin and is used for designing an optical detecting head. According to the device and the method, the concentration of a certain component in the turbid medium can be measured more accurately and conveniently, and the non-invasive, dynamic and continuous detection for the concentration of components in the turbid medium can be realized.

The invention provides a device and a method for detecting bilirubin for sclera imaging. A collecting lens, a diaphragm, a first optical lens and a transflective lens are placed from a lighting lightsource to a sclera in sequence; light is deflected by 90 degrees after passing through the transflective lens; and in the direction, a second optical lens, a trapezoidal prism, a third optical lens, aCCD and an external data processor are placed outwards from the transflective lens in sequence. According to the method, the thickness of the sclera is determined by measuring the brightness values of different points on the sclera, and the concentration numerical value of the bilirubin is determined by solving equations through the imaging brightness ratio under three wavelengths.

A method for measuring bilirubin concentration in a sample includes preparing a sensing element, where the sensing element may include a plurality of carbon dots, adding the sample to the sensing element, where the sample may include a plurality of bilirubin molecules, obtaining a first grayscale image of the sensing element under ultra-violet (UV) irradiation, irradiating visible light with a wavelength between 470 nm and 490 nm on the sensing element, obtaining a second grayscale image of the sensing element under ultra-violet (UV) irradiation, calculating a light intensity difference by calculating a difference between a first average light intensity of the first grayscale image and a second average light intensity of the second image, and determining the bilirubin concentration based on a correlation between the bilirubin concentration and the light intensity difference.